Please login to the form below

Not currently logged in
Email:
Password:

Trial success for Forest's depression drug

Forest Laboratories has said preliminary results from a phase III trial of major depressive disorder treatment, levomilnacipran, indicate the drug achieved a statistically significant improvement in patients compared to placebo

Forest Laboratories has said preliminary results from a phase III trial of major depressive disorder treatment, levomilnacipran, indicate the drug achieved a statistically significant improvement in patients compared to placebo.

The drug's efficacy was based on the primary endpoint of a patient's change from baseline to end of week 8 in the Montgomery-Asberg Depression Rating Scale-Clinician Rated (MADRS-CR) total score.

Levomilnacipran is co-developed by Forest and France-based laboratory Pierre Fabre Medicament.

"These positive phase III results are very encouraging and support the continued research of levomilnacipran in adult patients with major depressive disorder," said Dr Marco Taglietti, senior vice president, R&D, and president, Forest Research Institute.

Further analysis of the study data is ongoing, with two additional placebo-controlled phase III studies expected at the end of 2011 and in spring 2012, respectively.

18th July 2011

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Life Healthcare Communications

Life is a creative communications agency offering multi-channel solutions for the healthcare industry. We use a storytelling approach to turn...

Latest intelligence

Article:
The disparity of patient experiences with Crohn’s Disease in Europe and Japan...
Patient diversity in clinical trials
The pursuit of patient diversity in clinical trials
When all-inclusive isn’t an option, it’s an obligation...
Overcoming the digital patient recruitment challenges of connecting with patients
How many irrelevant experiences, ads, emails, direct messages have you rejected this week?...